180 Life Sciences Corp (ATNF)
1.97
-0.02
(-1.01%)
USD |
NASDAQ |
May 02, 16:00
1.97
0.00 (0.00%)
After-Hours: 20:00
180 Life Sciences Cash from Operations (TTM): -10.92M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -10.92M |
| September 30, 2023 | -11.69M |
| June 30, 2023 | -13.51M |
| March 31, 2023 | -13.92M |
| December 31, 2022 | -12.13M |
| September 30, 2022 | -14.23M |
| June 30, 2022 | -14.63M |
| Date | Value |
|---|---|
| March 31, 2022 | -15.11M |
| December 31, 2021 | -19.37M |
| September 30, 2021 | -17.56M |
| June 30, 2021 | -13.61M |
| March 31, 2021 | -9.793M |
| December 31, 2020 | -3.872M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-19.37M
Minimum
Dec 2021
-3.872M
Maximum
Dec 2020
-13.10M
Average
-13.61M
Median
Jun 2021
Cash from Operations (TTM) Benchmarks
| Seelos Therapeutics Inc | -23.91M |
| Altimmune Inc | -75.81M |
| GT Biopharma Inc | -8.852M |
| Outlook Therapeutics Inc | -47.10M |
| MAIA Biotechnology Inc | -13.07M |